Denali Therapeutics Inc.
Anti-ApoE antibodies
Last updated:
Abstract:
The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
Status:
Grant
Type:
Utility
Filling date:
27 Oct 2017
Issue date:
21 Sep 2021